Today, many biotechnology firms are using strategic alliances to contract with other companies. In this article, Professor Smith contends that the governance structure of these alliances—specifically, the “con-tractual board”—provides an integrated restraint on opportunism. While an alliance agreement’s exit structure could provide a check on oppor-tunism by allowing the parties to exit at will, such exit provisions also can be used opportunistically. Most alliance agreements, therefore, provide for contractual “lock in” of the alliance partners, with only limited means of exit. Lock in, of course, raises its own concerns, and Professor Smith contends that the contractual board—which is composed of representatives from each alliance partner, each wielding equal power—addresses these concerns about opportunism via the potential for deadlock.
The full text of this Symposium is available to download as a PDF.